Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial.

Turkova A, Waalewijn H, Chan MK, Bollen PDJ, Bwakura-Dangarembizi MF, Kekitiinwa AR, Cotton MF, Lugemwa A, Variava E, Ahimbisibwe GM, Srirompotong U, Mumbiro V, Amuge P, Zuidewind P, Ali S, Kityo CM, Archary M, Ferrand RA, Violari A, Gibb DM, Burger DM, Ford D, Colbers A, ODYSSEY Trial Team.

Open source

DOI: 10.1016/s2352-3018(22)00160-6
Published: 2022-07-19
Container: Lancet HIV
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s2352-3018-22-00160-6,
  title = {Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial.},
  author = {Turkova A and  Waalewijn H and  Chan MK and  Bollen PDJ and  Bwakura-Dangarembizi MF and  Kekitiinwa AR and  Cotton MF and  Lugemwa A and  Variava E and  Ahimbisibwe GM and  Srirompotong U and  Mumbiro V and  Amuge P and  Zuidewind P and  Ali S and  Kityo CM and  Archary M and  Ferrand RA and  Violari A and  Gibb DM and  Burger DM and  Ford D and  Colbers A and  ODYSSEY Trial Team.},
  year = {2022},
  journal = {Lancet HIV},
  doi = {10.1016/s2352-3018(22)00160-6},
  url = {https://doi.org/10.1016/s2352-3018(22)00160-6}
}

RIS

TY  - JOUR
TI  - Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial.
AU  - Turkova A
AU  -  Waalewijn H
AU  -  Chan MK
AU  -  Bollen PDJ
AU  -  Bwakura-Dangarembizi MF
AU  -  Kekitiinwa AR
AU  -  Cotton MF
AU  -  Lugemwa A
AU  -  Variava E
AU  -  Ahimbisibwe GM
AU  -  Srirompotong U
AU  -  Mumbiro V
AU  -  Amuge P
AU  -  Zuidewind P
AU  -  Ali S
AU  -  Kityo CM
AU  -  Archary M
AU  -  Ferrand RA
AU  -  Violari A
AU  -  Gibb DM
AU  -  Burger DM
AU  -  Ford D
AU  -  Colbers A
AU  -  ODYSSEY Trial Team.
PY  - 2022
JO  - Lancet HIV
DO  - 10.1016/s2352-3018(22)00160-6
UR  - https://doi.org/10.1016/s2352-3018(22)00160-6
ER  -

APA

A, T., H, W., MK, C., PDJ, B., MF, B., AR, K., MF, C., A, L., E, V., GM, A., U, S., V, M., P, A., P, Z., S, A., CM, K., M, A., RA, F., A, V., DM, G., DM, B., D, F., A, C., & Team., O. T. (2022). Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial.. Lancet HIV. https://doi.org/10.1016/s2352-3018(22)00160-6

Source records

europe-pmc · retrieved 2026-09-26T00:22:09.308Z
hal · retrieved 2026-09-26T00:22:09.347Z